Company Overview and News
Last week, the 3DExperience company Dassault Systèmes launched SolidWorks 2019—the newest portfolio of its 3D design and engineering applications—in India. The company said SolidWorks 2019 delivers “enhancements and functionalities that can help innovators improve the product development process, and create new experiences for customers.”
Solidworks, Dassault Systèmes’ 3D design software unit, is betting on India growth story as it sees the country as one of the most important markets for growth.
Across the aerospace and defence industry, rising customer expectations (lower costs, higher standards and increase capabilities) along with growing programme complexity make it more challenging to compete. As systems become more complex to design, build and deliver, OEMs and suppliers need to accelerate innovation, drive efficiencies and move to the factory of the future to allow for greater agility on production rate.
StarVR partners with leading aviation application service provider and systems integrator Avic Vision The company also joins the Industry of Virtual Reality Alliance to actively promote VR applications in aerospace
N.B. : Dassault Aviation comptabilise l'intégralité des contrats Rafale Export (y compris les parts Thales et Safran), alors que pour les marchés français n'est enregistrée que la part Dassault Aviation.
DUAVF AM DSYNV
Dassault Systèmes announced that Turkish Aerospace Industries, Inc. chose the 3DEXPERIENCE platform to accelerate the development of the TF-X aircraft, the newest and largest aviation development project in Turkey.
FOSHAN, China, June 18, 2018 (GLOBE NEWSWIRE) -- HP Inc. together with Guangdong (Dali) 3D Printing Collaborative Innovation Platform unveiled a new production-grade 3D printing center in China, the world’s largest manufacturing market. The Platform is powering its new Lanwan Intelligence – HP Multi Jet Fusion Technology Mass Manufacturing Center with 10 HP Multi Jet Fusion 3D printing systems to meet the growing demand for functional prototypes and production-grade parts.
(Saint-Cloud, France, le 28 mai 2018) - Dassault Aviation a signé avec Dassault Systèmes un accord de coopération pour la mise en place de la plateforme 3DEXPERIENCE au sein du groupe Dassault Aviation.
DUAVF AM DSYNV
(Saint-Cloud, May 28, 2018) - Dassault Aviation has signed a cooperation agreement with Dassault Systèmes for the implementation of the 3DEXPERIENCE platform within the Dassault Aviation group.
DUAVF AM DSYNV
Stratasys Ltd. (SSYS - Free Report) is scheduled to report first-quarter 2018 results on May 2. In the trailing four quarters, the company topped earnings estimates thrice, delivering an average beat of approximately 66.97%. Let’s take a look at how things are shaping up prior to this announcement. Factors to Consider Improving customer relationships and deeper market penetration are aiding the financials of Stratasys.
SSYS FEYE DSYNV CNA ARW STX PWR
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...